Blog | Monday, January 14, 2013

QD: News Every Day--NQF endorses 14 infectious disease quality measures

The National Quality Forum (NQF) endorsed 14 infectious disease quality measures, addressing issues such as appropriate treatment for upper respiratory infections, screening for tuberculosis and sexually transmitted diseases in HIV/AIDS patients, and vaccination and treatment for hepatitis C.

"Infectious diseases have a tremendous, adverse impact on our healthcare system and the health of our nation," said Helen Burstin, MD, MPH, FACP, senior vice president for performance measures at NQF. "These endorsed measures will be essential in helping providers evaluate patients, manage appropriate treatments, and ultimately improve patient care."

The measures are:
0058: Avoidance of antibiotic treatment in adults with acute bronchitis (NCQA)
0069: Appropriate treatment for children with upper respiratory infection (URI) (NCQA)
0395: Paired Measure: Hepatitis C ribonucleic acid (RNA) testing before initiating treatment (paired with 0396) (AMA-PCPI)
0396: Paired Measure: HCV genotype testing prior to treatment (paired with 0395)(AMA-PCPI)
0398: Hepatitis C: HCV RNA testing at no greater than week 12 of treatment (AMA-PCPI)
0399: Paired Measure: Hepatitis C: Hepatitis A vaccination (AMA-PCPI)
0404: HIV/AIDS: CD4 cell count or percentage performed (NCQA)
0405: HIV/AIDS: Pneumocystis jiroveci pneumonia (PCP) prophylaxis (NCQA)
0408: HIV/AIDS: Tuberculosis (TB) screening (NCQA)
0409: HIV/AIDS: Sexually transmitted diseases – Screening for chlamydia, gonorrhea, and syphilis (NCQA)
2079: HIV medical visit frequency (Health Resources and Services Administration - HIV/AIDS Bureau)
2080: Gap in HIV medical visits (Health Resources and Services Administration - HIV/AIDS Bureau)
2082: HIV viral load suppression (Health Resources and Services Administration - HIV/AIDS Bureau)
2083: Prescription of HIV antiretroviral therapy (Health Resources and Services Administration - HIV/AIDS Bureau)